Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
peginterferon alfa-2a · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | The dose of ribavirin used (fixed versus weight-based) is region dependent |
| Part B | EXPERIMENTAL | The dose of ribavirin used (fixed versus weight-based) is region dependent |
| Name | Type | Description |
|---|---|---|
| telaprevir or matching placebo | DRUG | Tablet, Oral, 750 mg, q8h, 12 weeks |
| peginterferon alfa-2a | BIOLOGICAL | Subcutaneous injection, 180 μg, once weekly, 48 weeks |
| ribavirin (fixed dose) | DRUG | Tablet, Oral, 800 mg, b.i.d., 48 weeks |
| ribavirin (weight-based dose) | DRUG | Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks |
| VCH-222 or matching placebo | DRUG | capsule, oral, 4 doses once daily or twice daily, 3 days |
| ribavirin | DRUG | tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks |
Inclusion Criteria: * Chronic, genotype 1, hepatitis C with detectable HCV RNA * HIV-1 infection for \>6 months * Documentation of a liver biopsy within 1 year before the screening visit showing evidence of hepatitis (demonstrated by inflammation and/or fibrosis) Exclusion Criteria: * Previous tr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Peginterferon alfa-2a is used for the treatment of Hepatitis C. It is being studied in combination with other antiviral agents, such as telaprevir and ribavirin, particularly in patients co-infected with HIV. The drug is currently in Phase 2 clinical development for this indication.
Peginterferon alfa-2a is being developed by Vertex Pharmaceuticals Incorporated, which is publicly traded under the ticker VRTX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating Hepatitis C.
Peginterferon alfa-2a is in Phase 2 clinical development for Hepatitis C. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in combination with other agents to assess its safety and efficacy.
Peginterferon alfa-2a has been studied in two completed clinical trials. One trial (NCT00911963) evaluated the pharmacokinetics of multiple ascending doses of VCH-222 in subjects with chronic Hepatitis C. Another trial (NCT00983853) assessed the safety and efficacy of telaprevir in combination with peginterferon alfa-2a and ribavirin in subjects co-infected with Hepatitis C and HIV.
No, peginterferon alfa-2a is not the same as VCH-222. In the clinical trial NCT00911963, VCH-222 is the investigational drug being studied, while peginterferon alfa-2a is used as a background therapy. The two are distinct agents with different mechanisms of action.